Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P18077
UPID:
RL35A_HUMAN
Alternative names:
60S ribosomal protein L35a; Cell growth-inhibiting gene 33 protein
Alternative UPACC:
P18077; Q08ES9; Q9BVN7
Background:
The Large ribosomal subunit protein eL33, also known as 60S ribosomal protein L35a and Cell growth-inhibiting gene 33 protein, plays a crucial role in protein synthesis. As a component of the large ribosomal subunit, it is pivotal in the cellular machinery for translating mRNA into polypeptides, thereby driving the expression of genetic information into functional proteins.
Therapeutic significance:
Given its essential function in hematopoietic cell proliferation and viability, the protein's involvement in Diamond-Blackfan anemia 5 highlights its potential as a target for therapeutic intervention. Understanding the role of Large ribosomal subunit protein eL33 could open doors to potential therapeutic strategies.